Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
RSV Breakthrough | Explore Enanta's progress in RSV treatment with zelicapavir, currently in Phase 2 trials for high-risk adults and pediatric patients, positioning the company as a potential leader in this field |
Immunology Pivot | Delve into Enanta's strategic shift towards immunology, featuring promising candidates for chronic spontaneous urticaria and atopic dermatitis, diversifying its therapeutic portfolio |
Financial Stability | Learn about Enanta's robust financial position, with $193 million in cash and an extended runway into fiscal year 2028, providing flexibility for pipeline advancement |
Market Potential | Analyst price targets range from $21 to $38, reflecting optimism about Enanta's diverse pipeline and potential in both antiviral and immunology markets |
Metrics to compare | ENTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENTAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.9x | −1.2x | −0.6x | |
PEG Ratio | −0.09 | −0.05 | 0.00 | |
Price/Book | 2.2x | 1.8x | 2.6x | |
Price / LTM Sales | 2.7x | 8.0x | 3.3x | |
Upside (Analyst Target) | 152.2% | 297.8% | 39.1% | |
Fair Value Upside | Unlock | 24.3% | 4.5% | Unlock |